James Fordyce

Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA.

VelQuest Corp. provides integrated compliance management solutions. The company's software is used by pharmaceutical companies to reduce compliance risk, liberate valuable resources and add value to existing document management and IT resources. Its SmartLab GMP Electronic Notebook System is built on electronic process management and compliance core operating system to provide the foundation for compliance based activities in the life science markets. The firm's services include planning and consulting, implementation, validation, customer education, field Service and customer support. VelQuest was founded in January, 1999 and is headquartered in San Diego, CA.

Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA.

MEDNA Partners LLC private advisory firm. The company is headquartered in Cambridge, MA.

Darwin Ventures LLC (Darwin Ventures) is a venture capital founded in 2002 by Peter Freudenthal and Frank R. Caufield. The firm is headquartered in Burlingame, California.

Ore Pharmaceuticals, Inc. operates as a drug development company, which developed drug candidates for therapeutic uses. The firm marketed its drug repositioning capabilities to pharmaceutical companies based in North America, Japan and Europe. The company was founded in September 1994 and was headquartered in Wellesley, MA.

Ore Holdings, Inc. is engaged in the provision of investment management services. It focuses on strategic investments aimed at enhancing the value of the entities within its portfolio. The company was founded in September 1994 and is headquartered in New York, NY.

Lotus Tissue Repair, Inc. develops dermatologic treatment technologies. Its solutions include a protein replacement therapy for the treatment of dystrophic epidermolysis bullosa, a group of genetic skin disease. The company was founded by Mei Chen, Mark P. de Souza, Philip R. Reilly, David Woodley and James W. Fordyce in 2011 and is headquartered in Lexington, MA.